Institution
Erasmus University Medical Center
Healthcare•Rotterdam, Zuid-Holland, Netherlands•
About: Erasmus University Medical Center is a healthcare organization based out in Rotterdam, Zuid-Holland, Netherlands. It is known for research contribution in the topics: Population & Medicine. The organization has 8162 authors who have published 11395 publications receiving 517117 citations.
Topics: Population, Medicine, Cancer, Transplantation, Breast cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Annual influenza vaccination is associated with a reduction in all-cause mortality risk in a population of community-dwelling elderly persons, particularly in older individuals.
Abstract: ContextAlthough large-scale observational studies have demonstrated the effectiveness
of influenza vaccination, no large studies have systematically addressed the
clinical benefit of annual revaccinations.ObjectiveTo investigate the effect of annual influenza revaccination on mortality
in community-dwelling elderly persons.Design, Setting, and ParticipantsA population-based cohort study using the computerized Integrated Primary
Care Information (IPCI) database in the Netherlands including community-dwelling
individuals aged 65 years or older from 1996 through 2002. For each year,
we computed the individual cumulative exposure to influenza vaccination since
study start.Main Outcome MeasureAssociation between the number of consecutive influenza vaccinations
and all-cause mortality vs no vaccination after adjusting for age, sex, chronic
respiratory and cardiovascular disease, hypertension, diabetes mellitus, renal
failure, and cancer.ResultsThe study population included 26 071 individuals, of whom 3485
died during follow-up. Overall, a first vaccination was associated with a
nonsignificant annual reduction of mortality risk of 10% (hazard ratio [HR],
0.90; 95% confidence interval [CI], 0.78-1.03) while revaccination was associated
with a reduced mortality risk of 24% (HR, 0.76; 95% CI, 0.70-0.83). Compared
with a first vaccination, revaccination was associated with a reduced annual
mortality risk of 15% (HR, 0.85; 95% CI, 0.75-0.96). During the epidemic periods
this reduction was 28% (HR, 0.72; 95% CI, 0.53-0.96). Similar estimates were
obtained for persons with and without chronic comorbidity and those aged 70
years or older at baseline. Overall, influenza vaccination is estimated to
prevent 1 death for every 302 vaccinees at a vaccination coverage that varied
between 64% and 74%.ConclusionAnnual influenza vaccination is associated with a reduction in all-cause
mortality risk in a population of community-dwelling elderly persons, particularly
in older individuals.
155 citations
••
TL;DR: The results suggest that the dynamics of ETO2 recruitment within nuclear complexes couple cell proliferation to cell differentiation and determine the onset of terminal erythroid maturation.
Abstract: The passage from proliferation to terminal differentiation is critical for normal development and is often perturbed in malignancies. To define the molecular mechanisms that govern this process during erythropoiesis, we have used tagging/proteomics approaches and characterized protein complexes nucleated by TAL-1/SCL, a basic helix–loop–helix transcription factor that specifies the erythrocytic lineage. In addition to known TAL-1 partners, GATA-1, E2A, HEB, LMO2 and Ldb1, we identify the ETO2 repressor as a novel component recruited to TAL-1 complexes through interaction with E2A/HEB. Ectopic expression and siRNA knockdown experiments in hematopoietic progenitor cells show that ETO2 actively represses erythroid TAL-1 target genes and governs the expansion of erythroid progenitors. At the onset of erythroid differentiation, a change in the stoichiometry of ETO2 within the TAL-1 complex activates the expression of known erythroid-specific TAL-1 target genes and of Gfi-1b and p21Cip, encoding two essential regulators of erythroid cell proliferation. These results suggest that the dynamics of ETO2 recruitment within nuclear complexes couple cell proliferation to cell differentiation and determine the onset of terminal erythroid maturation.
155 citations
••
TL;DR: Even for patients aged 60 years, event-free life expectancy is better with a bioprosthesis, although the chance of reoperation is higher, the lifetime risk of bleeding is lower compared with a mechanical prosthesis.
155 citations
••
TL;DR: It is suggested that, through its association with SCL, ETO-2 represses gene expression in the early stages of erythroid differentiation and that alleviation/modulation of the repressive state is then required for expression of genes necessary for terminal erythyroid maturation to proceed.
Abstract: Lineage specification and cellular maturation require coordinated regulation of gene expression programs. In large part, this is dependent on the activator and repressor functions of protein complexes associated with tissue-specific transcriptional regulators. In this study, we have used a proteomic approach to characterize multiprotein complexes containing the key hematopoietic regulator SCL in erythroid and megakaryocytic cell lines. One of the novel SCL-interacting proteins identified in both cell types is the transcriptional corepressor ETO-2. Interaction between endogenous proteins was confirmed in primary cells. We then showed that SCL complexes are shared but also significantly differ in the two cell types. Importantly, SCL/ETO-2 interacts with another corepressor, Gfi-1b, in red cells but not megakaryocytes. The SCL/ETO-2/Gfi-1b association is lost during erythroid differentiation of primary fetal liver cells. Genetic studies of erythroid cells show that ETO-2 exerts a repressor effect on SCL target genes. We suggest that, through its association with SCL, ETO-2 represses gene expression in the early stages of erythroid differentiation and that alleviation/modulation of the repressive state is then required for expression of genes necessary for terminal erythroid maturation to proceed.
155 citations
••
TL;DR: This randomized trial demonstrates that ATP has beneficial effects on weight, muscle strength, and QOL in patients with advanced NSCLC.
Abstract: textBACKGROUND: Extracellular adenosine 5'-triphosphate (ATP) is involved in
the regulation of a variety of biologic processes, including
neurotransmission, muscle contraction, and liver glucose metabolism, via
purinergic receptors. In nonrandomized studies involving patients with
different tumor types including non-small-cell lung cancer (NSCLC), ATP
infusion appeared to inhibit loss of weight and deterioration of quality
of life (QOL) and performance status. We conducted a randomized clinical
trial to evaluate the effects of ATP in patients with advanced NSCLC
(stage IIIB or IV). METHODS: Fifty-eight patients were randomly assigned
to receive either 10 intravenous 30-hour ATP infusions, with the infusions
given at 2- to 4-week intervals, or no ATP. Outcome parameters were
assessed every 4 weeks until 28 weeks. Between-group differences were
tested for statistical significance by use of repeated-measures analysis,
and reported P values are two-sided. RESULTS: Twenty-eight patients were
allocated to receive ATP treatment and 30 received no ATP. Mean weight
changes per 4-week period were -1.0 kg (95% confidence interval [CI] =
-1.5 to -0.5) in the control group and 0.2 kg (95% CI = -0.2 to +0.6) in
the ATP group (P =.002). Serum albumin concentration declined by -1.2 g/L
(95% CI= -2.0 to -0.4) per 4 weeks in the control group but remained
stable (0.0 g/L; 95% CI = -0.3 to +0.3) in the ATP group (P =.006). Elbow
flexor muscle strength declined by -5.5% (95% CI = -9.6% to -1. 4%) per 4
weeks in the control group but remained stable (0.0%; 95% CI= -1.4% to
+1.4%) in the ATP group (P =.01). A similar pattern was observed for knee
extensor muscles (P =.02). The effects of ATP on body weight, muscle
strength, and albumin concentration were especially marked in cachectic
patients (P =.0002, P =.0001, and P =. 0001, respectively, for ATP versus
no ATP). QOL score changes per 4-week period in the ATP group showed
overall less deterioration than in the control group-physical scores
(-0.2% versus -2.4%; P =. 0002); functional scores (+0.4% versus -5.5%; P
=.02); psychologic scores (-0.7% versus -2.4%; P =.11); overall QOL score
(+0.1% versus -3.5%; P =.0001). CONCLUSIONS: This randomized trial
demonstrates that ATP has beneficial effects on weight, muscle strength,
and QOL in patients with advanced NSCLC.
155 citations
Authors
Showing all 8309 results
Name | H-index | Papers | Citations |
---|---|---|---|
Albert Hofman | 267 | 2530 | 321405 |
André G. Uitterlinden | 199 | 1229 | 156747 |
Patrick W. Serruys | 186 | 2427 | 173210 |
Cornelia M. van Duijn | 183 | 1030 | 146009 |
Tien Yin Wong | 160 | 1880 | 131830 |
Monique M.B. Breteler | 159 | 546 | 93762 |
Marjo-Riitta Järvelin | 156 | 923 | 100939 |
Fernando Rivadeneira | 146 | 628 | 86582 |
Ewout W. Steyerberg | 139 | 1226 | 84896 |
J. Wouter Jukema | 124 | 785 | 61555 |
Bart W. Koes | 124 | 730 | 57630 |
Albert D. M. E. Osterhaus | 124 | 955 | 83678 |
Jan K. Buitelaar | 123 | 1004 | 61880 |
Frits R. Rosendaal | 122 | 763 | 69043 |
Johan P. Mackenbach | 120 | 783 | 56705 |